Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Aoxing Reports Progress in its Narcotic API Manufacturing JV

publication date: Oct 26, 2010
Aoxing Pharma reported its JV, which will produce narcotic drug APIs, has passed a GMP inspection conducted by the SFDA. The company expects its newly renovated facility to earn full GMP certification by the end of 2010, allowing manufacturing to begin in 2011. The JV will receive a capital investment of $15 million over 5 years. Initially, the entity will develop eight narcotic API products for the China market, but its potential product portfolio could exceed 30 products. More details....

Stock Symbol: (NYSE Amex: AXN)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital